News

The Menarini Group, a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, along with Georgiamune Inc., a clinical-stage biotechnology company

LGM Pharma, a leading provider of tailored API sourcing, contract analytical testing, and drug development services, today announced it has acquired Sannova Analytical, a contract research laboratory headquartered in Somerset, N.J. The acquisition expands LGM Pharma’s analytical testing services business by adding Good Laboratory Practice (GLP) bioanalysis

Okomera, a TechBio company that personalizes cancer management with its technology combining mini-vatars tumor, microfluidics and AI imaging, today announced the signing of a commercial agreement with Servier, an independent international pharmaceutical group, to use its technology in the development of new cancer treatments.

Merck, known as MSD outside of the United States and Canada, today announced the European Commission (EC) has approved KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Padcev® (enfortumab vedotin-ejfv), as neoadjuvant

Eton Pharmaceuticals, Inc., an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, and Aquestive Therapeutics, Inc. (“Aquestive”) (Nasdaq: AQST), a pharmaceutical company advancing medicines

Halozyme Therapeutics has expanded its global collaboration and licence agreement with argenx to develop and commercialise subcutaneous formulations for two additional exclusive targets using its ENHANZE® drug delivery technology.

Italfarmaco S.p.A. and VeriSIM Life have entered into a strategic collaboration to discover and develop novel histone deacetylase (HDAC)-targeted therapies for neuromuscular, fibrotic and rare diseases.

Immunome has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for IM-1340, an investigational antibody-drug conjugate (ADC) being developed for advanced solid tumours

AbbVie has partnered with Valkai to expand the use of AI across selected areas of clinical development.

Turbine and Daiichi Sankyo have expanded their collaboration to support antibody-drug conjugate (ADC) discovery using computational modelling.